Cancer and Non-cancer Hospice Patients
Conditions
Keywords
virtual reality, palliative care, Edmonton symptom assessment scale, Hospice, depression, anxiety, pain, shortness of breath, well-being
Brief summary
The objective of this study is to determine whether VR can ameliorate symptoms for palliative care patients within a hospice setting. We also aim to verify the efficacy with a larger sample size than previously shown, as well as extend the population to include non-cancer patients receiving Hospice care. We will further attempt to delineate whether there is a sustainability of symptomatic improvement one week after VR experiences.
Detailed description
Potential candidates will be provided with our assent and consent information form and the study will be explained to them in detail prior to gaining consent. As per standard practice at The Hospice of Windsor & Essex County, palliative care ESAS symptoms will be measured at baseline during the week prior to the VR experience. The mean of these pre-VR scores will be calculated as a baseline, optimally 3 separate ESAS scores in the preceding week. ESAS symptoms and expectations/satisfaction will then be measured immediately before and after the VR experience. An average set of ESAS scores will then be calculated in the same manner for one week post VR as per baseline pre-VR scores above. We expect to find a decrease in Palliative Care symptoms after the intervention of a VR experience.
Interventions
DEVICEVirtual Reality
The intervention is a Virtual Reality experience within a selected application using an Oculus Quest 2 ©, as previously in the relevant intervention arm.
Sponsors
Western University, Canada
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
SUPPORTIVE_CARE
Masking
NONE
Intervention model description
ESAS scores for 5 key symptoms (pain, shortness of breath, depression, anxiety, and well-being) and qualitative question(s) will be asked verbally by one of the investigators and recorded on an ipad directly into the Qualtrics form, before and after the VR session. Vital signs (blood pressure, heart rate, respiratory rate) will also be measured before and after the VR session. Participants will be given a list of VR applications to choose from. They will then be given instructions by a research assistant (approximately 10 minutes) on how to use the selected application using Oculus Quest 2 they have chosen, as well as time for any questions they may have before starting their VR experience. They will then have an approximately 30-minute session of that VR experience. They may or may not be accompanied by a family member or significant other and will also have a research assistant available to aid them in any difficulties experienced during the VR experience.
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
* at least 18 years or older * admitted to Hospice for Specialty Palliative Care
Exclusion criteria
* Palliative Performance Scale (PPS) ≤ 20% * severe cognitive impairment leading to inability to provide ESAS scores for 5 key symptoms measured in this study * severe visual and/or hearing impairment preventing use of VR (glasses and hearing aids may be worn during VR sessions and do not exclude participation) * absolute inability to sit * paralysis of an upper limb * participant dies before VR experience
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| VR experience effect on pain, shortness of breath, depression, anxiety, and well-being scores (0 - 10) | ESAS scores measured immediately before VR experience will be compared to ESAS scores measured immediately after VR experience | The primary outcome of this study will be a significant difference in change of ESAS score for 5 key symptoms (pain, shortness of breath, depression, anxiety, and well-being) immediately before and after a VR experience. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| VR experience longitudinal effect (one week later) on baseline pain, shortness of breath, depression, anxiety, and well-being scores (0 - 10) | Baseline average ESAS scores measured one week prior to the VR experience will be compared to the average of ESAS scores one week following the VR experience. | The first secondary outcome of this study will be a significant difference between the mean of the 1-week pre-VR and the mean of the 1-week post-VR ESAS scores for 5 key symptoms (pain, shortness of breath, depression, anxiety, and well-being). For more objective evaluation of pain and distress we will also be measuring vitals immediately before and immediately after each VR experience. |
| VR experience effect on Mean Arterial Pressure (MAP) (part of vital signs) as indicator for Pain and/or Distress | MAP measured immediately before and immediately after each VR experience. | For more objective evaluation of pain and distress, the investigators will be measuring blood pressure to compare the Mean Arterial Pressure (MAP; mmHg) immediately before and immediately after each VR experience. |
| VR experience effect on Heart Rate (HR) (part of vital signs) as indicator for Pain and/or Distress | HR measured immediately before and immediately after each VR experience. | For more objective evaluation of pain and distress, the investigators will be measuring Heart Rate (HR; beats per minute \[bpm\]) immediately before and immediately after each VR experience. |
| VR experience effect on Respiratory Rate (RR) (part of vital signs) as indicator for Pain and/or Distress | RR measured immediately before and immediately after each VR experience. | For more objective evaluation of pain and distress, the investigators will be measuring Respiratory Rate (RR; breaths per minute \[brpm\]) immediately before and immediately after each VR experience. |
Countries
Canada
Contacts
Primary ContactPatricia Valcke, MD
Backup ContactNatan Veinberg, MD
Outcome results
None listed